Eporatio

Epoetin theta

Symptomatic anaemia associated w/ chronic renal failure in adults; adult cancer patients w/ non-myeloid malignancies receiving chemotherapy.

Adult Symptomatic anaemia associated w/ chronic renal failure Correction phase: IV Initially 40 IU/kg thrice wkly. May be increased to 80 IU/kg thrice wkly after 4 wk, then increase to 25% of previous dose mthly. SC Initially 20 IU/kg thrice wkly. May be increased to 40 IU/kg thrice wkly after 4 wk, then further increase to 25% of previous dose mthly until target Hb level is obtained. Maintenance phase: IV Switch to twice wkly. SC 1 inj wkly or thrice wkly. IV/SC Max: Not to exceed 700 IU/kg wkly. Symptomatic anaemia in cancer patients w/ non-myeloid malignancies receiving chemotherapy SC/IV Initially 20,000 IU once wkly. May be increased to 40,000 IU once wkly after 4 wk, then increase to 60,000 IU once wkly after an additional 4 wk. Max: Not to exceed 60,000 IU wkly. Treatment duration: Up to 4 wk after the end of chemotherapy.

Hypersensitivity to epoetin theta & other epoetins. Uncontrolled HTN.

Severe cutaneous AR eg, SJS & TEN. Discontinue treatment if patient has sudden drop in Hb associated w/ reticulocytopenia. W/draw immediately if skin reactions occur. Not to be used in patients w/ advanced head & neck cancer receiving RT; metastatic breast cancer receiving chemotherapy; active malignant disease receiving neither chemotherapy nor RT. Intercurrent infections, inflammatory or traumatic episodes, occult blood loss, haemolysis, Al intoxication, underlying haematological diseases or bone marrow fibrosis. Patients w/ suspected or confirmed neutralising Ab to erythropoietin; homozygous sickle anemia; poor Hb response. Increased BP or aggravation of existing HTN. Evaluate Fe status prior to & during treatment. Correct Fe, folic acid or vit B₁₂ deficiencies. Monitor closely & control BP prior to & during therapy. Consider reticulocyte count. Perform regular Hb measurement, complete blood & platelet count. Concomitant use w/ interferon & ribavirin. Impaired liver function. Chronic renal failure. Avoid use during pregnancy. Lactation. Childn & adolescents ≤17 yr. Elderly >75 yr.

Headache; HTN, hypertensive crisis, shunt thrombosis; skin reaction; arthralgia; flu-like illness.

Haematopoietic Agents

B03XA01 - erythropoietin ; Belongs to the class of other antianemic preparations. Used in the treatment of anemia.

S